Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:GBY Stock Latest News

Company AnnouncementsSangamo Therapeutics Updates Chapter 11 Operating Reports5d ago8K

Company AnnouncementsSangamo Therapeutics Highlights Risks Amid Ongoing Bankruptcy2w ago8K
Company AnnouncementsSangamo Therapeutics Completes Fabry Gene Therapy Asset Sale1M ago8K
Company AnnouncementsSangamo Therapeutics Completes Key Technology Asset Sale1M ago8K
Company AnnouncementsSangamo Therapeutics Signs Asset Sale Deal Amid Bankruptcy2M ago8K

Sangamo Therapeutics Delays Quarterly 10-Q Filing

Company AnnouncementsSangamo Therapeutics Delays Quarterly 10-Q Filing2M ago

Company AnnouncementsSangamo Concludes Section 363 Asset Sales in Bankruptcy2M ago8K

Company AnnouncementsSangamo Therapeutics Reports Post-Bankruptcy Operating Developments2M ago8K

Pre-EarningsSGMO Earnings Report this Week: Is It a Buy, Ahead of Earnings?2M ago
Company AnnouncementsSangamo Therapeutics Advances Bankruptcy Asset Sale Process3M ago8K
Company AnnouncementsSangamo Shares Shift to OTC Market Amid Bankruptcy4M ago8K
The FlyFive new option listings and two option delistings on June 24th4M agoGLOO QTTB

Sangamo files for restructuring, plans asset sales to Lilly, Astellas

The FlySangamo files for restructuring, plans asset sales to Lilly, Astellas4M agoLLY SGMO

Company AnnouncementsSangamo Therapeutics Initiates Chapter 11 and Asset Sales4M ago8K SGMO

The FlySangamo price target lowered to $5 from $10 at H.C. Wainwright5M agoSGMO

Company AnnouncementsSangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period5M agoSGMO
Company AnnouncementsSangamo Biosciences Balances Fabry Progress With Cash Strain5M agoSGMO
RatingsSangamo Therapeutics: Partnering-Driven Path to 2027 Fabry Gene Therapy Launch Supports Buy Rating and $10 Target7M agoSGMO
Company AnnouncementsSangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty7M agoSGMO

Sangamo Biosciences Balances Fabry Progress With Cash Risk

Company AnnouncementsSangamo Biosciences Balances Fabry Progress With Cash Risk7M agoSGMO

The FlySangamo reports Q4 EPS (11c), consensus (5c)7M agoSGMO

The FlySangamo sees FY26 operating expenses $8M7M agoSGMO